Colorectal carcinoma
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Colorectal carcinoma
- Therapeutic area
- Gastroenterology
- colorectal carcinoma
- cancer of large bowel
- cancer of large intestine
- cancer of the large bowel
- cancer of the large intestine
- colorectal (colon or rectal) cancer
- colorectal cancer
- large bowel cancer
- large intestine cancer
- CRC
- carcinoma of colorectum
- carcinoma of large bowel
- carcinoma of large intestine
- carcinoma of the large bowel
- carcinoma of the large intestine
- colorectal carcinoma
- colorectum carcinoma
- large bowel carcinoma
- large intestine carcinoma
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0024331
- Parent condition
- MONDO:0005575
Related records
Broader conditions (20)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Colorectal cancer
- Colorectal neoplasm
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Intestinal cancer
- Intestinal disorder
- Intestinal neoplasm
- Large intestine disorder
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (57)
- Adenosquamous colon carcinoma
- Anal canal adenocarcinoma
- Anal canal carcinoma
- Anal canal carcinoma in situ
- Anal canal neuroendocrine neoplasm
- Anal canal Paget disease
- Anal canal squamous cell carcinoma
- Anal carcinoma
- Anal gland adenocarcinoma
- Anal margin basal cell carcinoma
- Anal margin carcinoma
- Anal margin squamous cell carcinoma
- Anal mucinous adenocarcinoma
- Anal Paget disease
- Anal squamous cell carcinoma
- Anal verrucous carcinoma
- Anus adenocarcinoma
- Anus basaloid carcinoma
- Appendix adenocarcinoma
- Appendix carcinoma
Trials (501)
- 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
- 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
- A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
- A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
- A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
- A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
- A Community-Based Educational Intervention to Improve Colorectal Cancer Screening
- A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
- A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
- A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
- A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
- A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
- A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial
Approved drugs (12)
- Bevacizumab
- Capecitabine
- Cetuximab
- Ipilimumab
- Levoleucovorin
- Levoleucovorin calcium
- Nivolumab
- Panitumumab
- Regorafenib
- Tipiracil hydrochloride
- Trifluridine
- Tucatinib
Drugs in development (59)
- Abituzumab Phase 1
- Atezolizumab Phase 3
- Avelumab Phase 2
- Axitinib Phase 2
- Berzosertib Phase 1
- Binimetinib Phase 2
- Bortezomib D-mannitol Phase 2
- Cadonilimab Phase 2
- Calcium Phase 3
- Camrelizumab Phase 2
- Celecoxib Phase 3
- Clobetasol propionate Phase 2
- Cobimetinib Phase 3
- Daratumumab Phase 2
- Dolcanatide Phase 1
- Dostarlimab Phase 2
- Doxycycline Phase 2
- Durvalumab Phase 2
- Fluorouracil Phase 3
- Fruquintinib Phase 2